ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
In Situ Neutralization and Detoxification of LPS to Attenuate Hyperinflammation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Emerging trends and hotspots in intestinal microbiota research in sepsis: bibliometric analysis.Frontiers in medicine · 2024Pooled it
- 4-octyl itaconate alleviates LPS-induced inflammation in Sertoli cells by inhibiting excessive autophagy.Redox biology · 2026Article
- Lipopolysaccharide hydrolysis-targeting nano-chimeras detoxify endotoxin through specific adsorption and efficient degradation.Nature communications · 2026Article
- Engineering a T7 bacteriophage to attenuate LPS-driven inflammatory responses during bacteriolysis.Applied and environmental microbiology · 2026Article
- Dietary Glyceryl Monolaurate Supplementation During Pregnancy Enhances Fetal Intrauterine Development and Antioxidant Capacity in Sows via Microbiota Modulation.Antioxidants (Basel, Switzerland) · 2025Article
- Methionine-driven methylation modification overcomes plasmid-mediated high-level tigecycline resistance.Nature communications · 2025Article
- Gut Microbiota Metabolites Targeting the Immune Response in Sepsis: Mechanisms and Therapies.International journal of general medicine · 2025Review
- High Stability and Low Irritation of Enrofloxacin-Colistin Combination Injection Through a Tripartite Strategy.Drug design, development and therapy · 2025Article
- Nanodrug Delivery Systems for Direct Clearance or Neutralization of LPS.International journal of nanomedicine · 2025Review
- Neutralizing gut-derived lipopolysaccharide as a novel therapeutic strategy for severe leptospirosis.eLife · 2024Article
- Radiation-Detoxified Form of Endotoxin Effectively Activates ThInternational journal of molecular sciences · 2024Article
- In Situ Neutralization and Detoxification of LPS to Attenuate Hyperinflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Hyperinflammation elicited by lipopolysaccharide (LPS) that derives from multidrug-resistant Gram-negative pathogens, leads to a sharp increase in mortality globally. However, monotherapies aiming to neutralize LPS often fail to improve the prognosis. Here, an all-in-one drug delivery strategy equipped with bactericidal activity, LPS neutralization, and detoxification is shown to recognize, kill pathogens, and attenuate hyperinflammation by abolishing the activation of LPS-triggered acute inflammatory responses. First, bactericidal colistin results in rapid bacterial killing, and the released LPS is subsequently sequestered. The neutralized LPS is further cleared by acyloxyacyl hydrolase to remove secondary fatty chains and detoxify LPS in situ. Last, such a system shows high efficacy in two mouse infection models challenged with Pseudomonas aeruginosa. This approach integrates direct antibacterial activity with in situ LPS neutralizing and detoxifying properties, shedding light on the development of alternative interventions to treat sepsis-associated infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.